Contrast developer Bracco Diagnostics of Princeton, NJ, has received an approvable letter from the Food and Drug Administration for its MultiHance MRI contrast agent. Targeted at central nervous system (CNS) imaging applications, MultiHance (gadobenate dimeglumine) is a paramagnetic positive contrast agent that features a weak and reversible protein interaction, according to Bracco.
This interaction increases relaxivity, Bracco said, yielding high efficiency in CNS imaging. MultiHance is already approved and being marketed in Europe.
By AuntMinnie.com staff writersNovember 25, 2002
Related Reading
Mobile PET, Bracco team up, October 10, 2002
Bracco bids to take Esaote private, October 8, 2002
Bracco takes majority stake in Volume Interactions, February 21, 2002
Copyright © 2002 AuntMinnie.com
